U.S. markets open in 30 minutes

HC2 Holdings, Inc. (HCHC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
3.6900+0.1900 (+5.43%)
At close: 4:00PM EST

3.6900 0.00 (0.00%)
Pre-Market: 8:08AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close3.5000
Open3.6000
Bid0.0000 x 900
Ask3.7700 x 900
Day's Range3.5600 - 3.7400
52 Week Range1.2900 - 4.7500
Volume190,901
Avg. Volume774,825
Market Cap282.605M
Beta (5Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-2.6070
Earnings DateMar 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 28, 2013
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-6% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • HC2 Holdings to Report Fourth Quarter and Full Year 2020 Results on March 10
    GlobeNewswire

    HC2 Holdings to Report Fourth Quarter and Full Year 2020 Results on March 10

    NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC), announced today that it will release its financial results for the fourth quarter and full year 2020 on Wednesday, March 10, 2021 after the market closes. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 5:00 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through HC2’s Investor Relations website at ir.hc2.com. To listen to the live call, please go to the “Investor Relations” section of the Company’s website at least 15 minutes prior to the start of the call to register and download any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call on the “Investor Relations” portion of the HC2 website. Conference Call Details Live CallDial-In: 1-877-705-6003International Dial-In: 1-201-493-6725Conference Number: 13717091 Conference Replay*Domestic Dial-In (Toll Free): 1-844-512-2921International Dial-In: 1-412-317-6671Conference Number: 13717091 *Available approximately two hours after the end of the conference call through March 24, 2021. About HC2 HC2 Holdings, Inc. (NYSE: HCHC) has a class-leading portfolio of subsidiaries in Infrastructure, Life Sciences, Spectrum and Insurance. HC2 is headquartered in New York, NY, and through its subsidiaries employs over 2,800 people. Contacts Investor Contact: FNK IRMatt Chesler, CFAir@hc2.com(212) 235-2691 Media Contact:ReevemarkPaul Caminiti/Pam Greene/Luc HerbowyHC2@reevemark.com(212) 433-4600

  • HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment
    GlobeNewswire

    HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment

    Investment to Fund Launch of First-to-Market Glacial Rx™ and Glacial Spa™ Aesthetic Skin TreatmentsNEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2’s portfolio company Pansend Life Sciences (“Pansend”), has received $10 million in funding from Huadong Medicine Company Limited (“Huadong”), a leading publicly traded Chinese pharmaceutical company. Huadong’s investment will be used to fund the launch of R2 Technologies’ first-to-market innovations Glacial Rx™ and Glacial Spa™. In exchange for its equity investment in R2, Huadong receives exclusive distribution rights for R2’s products in the China and selected Asia-Pacific markets. Glacial Rx is the first CryoAesthetic™ age spot removal treatment that is FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation, and Glacial Spa is a unique cooling experience that brightens and evens skin tone. R2 will commence the distribution of Glacial Rx to U.S. aesthetic providers and the distribution of Glacial Spa to high-end spas in China. “We appreciate Huadong’s continued investment and believe their commitment to R2 is a testament to the significant market opportunity for these revolutionary products,” said Wayne Barr, Chief Executive Officer of HC2. “Pansend Life Sciences is a key component of HC2’s business, and we look forward to driving continued growth in this dynamic and evolving sector.” Tim Holt, R2 Chief Executive Officer, added, “We are proud to have the Huadong team’s wealth of knowledge as both an investor and strategic business partner supporting our mission. We look forward to our future successes together as we bring Glacial Rx and Glacial Spa to market.” This investment constitutes the third and final tranche of Huadong’s $30 million equity investment at a predetermined post-money valuation of $113 million for R2, established at the time of R2’s Series B close in June 2019. R2 is actively taking orders for aesthetic providers who want to offer the new Glacial Rx treatment in-office. To learn more about R2 Technologies and its upcoming launch, visit glacialskin.com and follow the company on LinkedIn. About HC2 HC2 Holdings, Inc. (NYSE: HCHC) has a class-leading portfolio of assets primarily in Infrastructure, Life Sciences, Spectrum and Insurance. HC2 is headquartered in New York, New York and through its subsidiaries employs 2,848 people. About Pansend Life Sciences Pansend Life Sciences, LLC is the life sciences subsidiary of HC2 Holdings, Inc., focused on the development of innovative healthcare technologies and products. Pansend’s portfolio companies include R2 Technologies, which is developing medical devices for the treatment of aesthetic and medical skin conditions and has received FDA approval for its initial device; MediBeacon, whose proprietary platform technology is the foundation of its development of a non-invasive real-time monitoring system for the evaluation of kidney function; Triple Ring, a leading edge research, engineering and development firm which specializes in regulated medical devices, in vitro diagnostics & life sciences tools as well as imaging, and industrial applications; and Genovel Orthopedics, which is developing novel partial and total knee replacements for the treatment of osteoarthritis of the knee. In 2018, Pansend’s portfolio company BeneVir was acquired by Janssen Biotech, Inc. (Johnson & Johnson) for up to $1.04 billion. About R2 Technologies Headquartered in Silicon Valley, R2 Technologies is a world leader in CryoAesthetic™ medical devices. In 2014, Pansend Life Sciences, LLC and Blossom Innovations, LLC founded R2 Technologies and licensed exclusive intellectual property from Massachusetts General Hospital. In 2019, R2 brought on strategic partner, Huadong Medicine Co., Ltd. In close collaboration with these partners and the brand’s scientific founders and world-famous luminaries in aesthetic medicine, Drs. Rox Anderson, Dieter Manstein, and Henry Chan, R2 focuses on the development, engineering, clinical research, and commercialization of groundbreaking technologies for aesthetic providers and consumers. Since inception, R2 has raised $62 million in financing led by a world-class team of experts within the aesthetics industry. Cautionary Statement Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements regarding building shareholder value and future cash flow and invested assets. All forward-looking statements speak only as of the date made, and unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Contacts Media Contact:ReevemarkPaul Caminiti/Pam Greene/Luc HerbowyHC2@reevemark.com(212) 433-4600 Investor Contact: FNK IRMatt Chesler, CFAir@hc2.com(212) 235-2691

  • GlobeNewswire

    HC2 Holdings Announces Upsizing and Pricing of $330 Million Senior Secured Notes Offering

    NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, announced today the pricing of an offering of 8.500% senior secured notes due 2026 (the “Notes”) at an issue price of 100%. The size of the offering has been upsized from $300 million to $330 million aggregate principal amount of the Notes. The Notes will be senior secured obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries. The offering of the Notes is expected to close on February 1, 2021, subject to customary closing conditions. In addition, the Company expects to close its previously announced convertible notes exchange on the same date, subject to customary closing conditions. The proceeds from the issuance of the Notes are expected to be used, together with the net cash proceeds of the Company’s previously announced sale of its majority-owned subsidiary Beyond6, Inc., to redeem in full HC2’s existing 11.500% senior secured notes, repay the outstanding indebtedness under its revolving credit agreement, pay related fees and expenses, and for general corporate purposes. The Notes and the New Convertible Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. The Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act, and the New Convertible Notes are expected to be issued in one or more private exchange transactions pursuant to an exemption from registration under the Securities Act. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale of any security in any jurisdiction in which such offer, solicitation or sale would be unlawful. About HC2 HC2 (NYSE: HCHC) has a class-leading portfolio of assets primarily in Infrastructure, Life Sciences, Spectrum and Insurance. HC2 is headquartered in New York, New York and through its subsidiaries employs 2,864 people. Cautionary Statement Regarding Forward-Looking Statements Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements regarding the proposed refinancing transactions, including, among others, the use of proceeds from the issuance of the Notes and the expected closing date of the offering of the Notes and the convertible notes exchange, all of which involve risks, assumptions and uncertainties, many of which are outside of the Company's control, and are subject to change. All forward-looking statements speak only as of the date made, and unless legally required, HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Media Contact:ReevemarkPaul Caminiti/Pam Greene/Luc HerbowyHC2@reevemark.com(212) 433-4600 Investor Contact: FNK IRMatt Chesler, CFAir@hc2.com(212) 235-2691